Mechanisms involved in the induction of malignant cell differentiation.
Cancer appears to be a disease of altered maturation, with changes in genetic expression leading to a situation in which the physiological regulation of cellular proliferation and maturation are altered. Environmental factors as well as defined chemical agents have been demonstrated to have the capacity to convert neoplastic cells to end-stage forms with a finite life span through a process characteristic of cellular maturation. The correction of genetic defects by these inducers of differentiation does not appear to be required; the critical feature is that the differentiated cells assume a state in which they no longer possess the capability for continued cellular replication. The extrapolation of these advances, accomplished in experimental systems, to clinical practice should yield significant decreases in the neoplastic cell burden without the degree of morbidity produced by aggressive therapy with cytodestructive agents, especially when employed in multidrug combinations. The ultimate introduction of differentiation as a therapeutic approach to cancer treatment if attained, however, will require a variety of principles to be established, so that optimum efficacy may be obtained from each agent, the fabrication of new agents with major changes in the ratio of the concentrations required to produce cytotoxicity relative to those necessary to initiate maturation is attained, and the elucidation of non-antagonistic combinations of differentiation inducing agents with or without cytotoxic drugs is achieved to combat the problem of tumor cell heterogeneity.
D000818:Animals; D000903:Antibiotics, Antineoplastic; D002294:Carcinoma, Squamous Cell / Q000235:genetics / Q000473:pathology; D002460:Cell Line; D002470:Cell Survival / Q000187:drug effects; D002471:Cell Transformation, Neoplastic / Q000187:drug effects / Q000473:pathology*; D006801:Humans; D006854:Hydrocortisone / Q000494:pharmacology; D007942:Leukemia, Experimental / Q000473:pathology; D008954:Models, Biological; D009279:Naphthacenes / Q000494:pharmacology; D010641:Phenotype; D013866:Thioguanine / Q000494:pharmacology; D014212:Tretinoin / Q000494:pharmacology
D000903:Antibiotics, Antineoplastic; D009279:Naphthacenes; D014212:Tretinoin; D013866:Thioguanine; D006854:Hydrocortisone